NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 284)
Posted On: 10/24/2019 5:01:24 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applauds FDA Forward-Looking Decision on Reduced Risk Tobacco Format
Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration (“FDA”), for the first time ever, has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway. According to the update, this pathway includes product categories that could benefit from Lexaria’s technology. The FDA-authorized product format is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there is no need to spit. Significantly, because there is no combustion, heating or vaporization of the tobacco pouch during use, as well as FDA-accepted scientific evidence that included long-term epidemiological studies in association with this approval, claims of a lower risk of mouth cancer, stroke, lung disease, heart disease, emphysema and chronic bronchitis than cigarettes are permitted by the FDA. “Lexaria applauds this informed and forward-looking decision by the FDA to recognize improvements in delivery formats that are being made by industry,” Lexaria Bioscience Corp. CEO Chris Bunka said in the news release. “Lexaria realized long ago that DehydraTECH(TM) could empower alternative nicotine product formats and as a result our delivery technology which is already patented in the U.S. and patent pending around the world for enhanced oral nicotine delivery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration (“FDA”), for the first time ever, has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway. According to the update, this pathway includes product categories that could benefit from Lexaria’s technology. The FDA-authorized product format is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there is no need to spit. Significantly, because there is no combustion, heating or vaporization of the tobacco pouch during use, as well as FDA-accepted scientific evidence that included long-term epidemiological studies in association with this approval, claims of a lower risk of mouth cancer, stroke, lung disease, heart disease, emphysema and chronic bronchitis than cigarettes are permitted by the FDA. “Lexaria applauds this informed and forward-looking decision by the FDA to recognize improvements in delivery formats that are being made by industry,” Lexaria Bioscience Corp. CEO Chris Bunka said in the news release. “Lexaria realized long ago that DehydraTECH(TM) could empower alternative nicotine product formats and as a result our delivery technology which is already patented in the U.S. and patent pending around the world for enhanced oral nicotine delivery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)